Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
Background/Aim: To evaluate the association between baseline [18F]FDG-PET/CT tumor burden parameters and disease progression rate after first-line target therapy or immunotherapy in advanced melanoma patients. Materials and Methods: Forty four melanoma patients, who underwent [18F]FDG-PET/CT before...
Guardado en:
Autores principales: | Virginia Liberini, Marco Rubatto, Riccardo Mimmo, Roberto Passera, Francesco Ceci, Paolo Fava, Luca Tonella, Giulia Polverari, Adriana Lesca, Marilena Bellò, Vincenzo Arena, Simone Ribero, Pietro Quaglino, Désirée Deandreis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/066e395753a74684b6a1ceafa6566f8f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment of Advanced Metastatic Melanoma
por: Pietro Quaglino, et al.
Publicado: (2021) -
Development of Indole Alkaloid-Type Dual Immune Checkpoint Inhibitors Against CTLA-4 and PD-L1 Based on Diversity-Enhanced Extracts
por: Yoshihide Suzuki, et al.
Publicado: (2021) -
Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma
por: Pei-Yi Chu, et al.
Publicado: (2021) -
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
por: I. O. Chikileva, et al.
Publicado: (2019) -
Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
por: Utpal Kumar, et al.
Publicado: (2021)